CAR T Cells: A Living Targeted Drug, With Dr Matt Cooper

Posted by

Teach Me in 10

In this installment of Teach Me in 10, we're joined by Matt Cooper, co-founder and chief scientific officer at Wugen, Inc. He is also assistant professor of medicine at Washington University. Matt discusses what T cells are and how they can be engineered to recognize cancer cells. This can be achieved by incorporating a specific receptor – the chimeric antigen receptor (CAR) – which results in the generation of CAR T cells. “CAR T cells are essentially a living targeted drug,” says Matt. Learn more about the key challenges related to engineering CAR T cells, discover ways to enable the broader application of these cells and hear about the development of allogeneic CAR T cells as an “off-the-shelf” treatment for cancer. You can learn more about CAR T cells by checking out the following content: Treating Cancer – 5 Types of Immunotherapy, Opinionated Science Episode 14: Cancer Immunotherapy: Vaccines, Viruses and Nobel Prizes and Cancer and the Immune System.